

University of Groningen

Studies on Ligand Directed Enzyme Prodrug Therapy and Production of Long Acting Protein Therapeutics for Targeted Cancer Treatment

Al-Mansoori, Layla

DOI:
[10.33612/diss.131689831](https://doi.org/10.33612/diss.131689831)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2020

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Al-Mansoori, L. (2020). *Studies on Ligand Directed Enzyme Prodrug Therapy and Production of Long Acting Protein Therapeutics for Targeted Cancer Treatment*. University of Groningen.
<https://doi.org/10.33612/diss.131689831>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

**Studies on Ligand Directed
Enzyme Prodrug Therapy and
Production of Long Acting Protein
Therapeutics for Targeted Cancer
Treatment**

Layla Jeda R A Al-Mansoori

The research described in this thesis was conducted in the Protein Engineering Lab, Research Department, at Anti-doping Laboratory Qatar (ADLQ). The work was financially supported by Qatar National Research Fund (QNRF) NPRP6-065-3-012 and Qatar University (QU), Doha - Qatar.

The author gratefully thanks QNRF and QU for funding part of this work, and University Medical Center Groningen (UMCG) and ADLQ for facilitating the research.



مختبر مكافحة
المنشطات قطر
Anti Doping
Lab Qatar

Cover design and layout: picture obtained from <https://www.cancercenter.com/community/blog/2018/02/how-does-cancer-do-that-cancer-cells-find-ways-to-resist-treatment> and modified by Layla Al-Mansoori.

Printed by: Aspire Printing Press / Qatar.

© Copyright 2020, Layla Al-Mansoori. All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system, or transmitted in any form or by any means without prior permission of the author.



university of
 groningen

Studies on Ligand Directed Enzyme Prodrug Therapy and Production of Long Acting Protein Therapeutics for Targeted Cancer Treatment

PhD thesis

to obtain the degree of PhD at the
University of Groningen
on the authority of the
Rector Magnificus Prof. C. Wijmenga
and in accordance with
the decision by the College of Deans.

This thesis will be defended in public on

Monday 14th September 2020 at 09.00 hours

by

Layla Al-Mansoori

born on 17 September 1974
in Doha-Qatar

Supervisors

Prof. P.H. Elsinga
Prof. S.K. Goda

Assessment Committee

Prof. A.S.S. Dömling
Prof. F. Kuipers
Prof. L. Chouchane

Table of Content

Chapter 1: <i>General Introduction of Thesis</i>	7
Chapter 2: <i>Studies on Ligand Directed Enzyme Prodrug Therapy & Production of Long-Acting Protein Therapeutics for Targeted Cancer Treatment</i>	17
Chapter 3:	75
<i>Production of “biobetter” glucarpidase variants to improve drug detoxification and antibody directed enzyme prodrug therapy for cancer treatment.</i>	
Chapter 4:	115
<i>In vitro studies on CNGRC-CPG2 fusion proteins for ligand-directed enzyme prodrug therapy for targeted cancer therapy.</i>	
Chapter 5:	151
<i>Production of long-acting CNGRC-CPG2 fusion proteins: New derivatives to overcome drug immunogenicity of ligand directed enzyme prodrug therapy for targeted cancer treatment</i>	
Chapter 6: <i>General Discussion and future perspectives</i>	177
Chapter 7: <i>Summary</i>	189
Chapter 8: <i>Samenvatting</i>	195
Chapter 9: <i>ملخص الرسالة</i>	201
Acknowledgements	206

